The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Abstract
A number of hypotheses regarding how anti‐Aβ antibodies alter amyloid deposition have been postulated, yet there is no consensus as to how Aβ immunotherapy works. We have examined the in vivo binding properties, pharmacokinetics, brain penetrance, and alterations in Aβ levels after a single peripheral dose of anti‐Aβ antibodies to both wild‐type (WT) and young non‐Aβ depositing APP and BRI‐Aβ42 mice. The rapid rise in plasma Aβ observed after antibody (Ab) administration is attributable to prolongation of the half‐life of Aβ bound to the Ab. Only a miniscule fraction of Ab enters the brain, and despite dramatic increases in plasma Aβ, we find no evidence that total brain Aβ levels are significantly altered. Surprisingly, cerebral spinal fluid Aβ levels transiently rise, and when Ab:Aβ complex is directly injected into the lateral ventricles of mice, it is rapidly cleared from the brain into the plasma where it remains stable. When viewed in context of daily turnover of Aβ, these data provide a framework to evaluate proposed mechanisms of Aβ attenuation mediated by peripheral administration of an anti‐Aβ monoclonal antibody (mAb) effective in passive immunization paradigm. Such quantitative data suggest that the mAbs are either indirectly enhancing clearance of Aβ or targeting a low abundance aggregation intermediate.—Levites, Y., Smithson, L. A., Price, R. W., Dakin. R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Reed, D. K., Rosenberry, T. L., Das, P., Golde, T. E. Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models. FASEB J. 20, E2002–E2014 (2006)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Flagged first, then by citations
Research works printed but not linked: 3
- Levites Y., 2005, Anti‐Abeta42 and Anti‐Abeta40 specific monoclonal antibodies attenuate amyloid deposition in an Alzheimer's disease mouse model, J. Clin. Invest, 116, 193, 10.1172/jci25410 · DOI
- Lee E. B., 2005, Targeting Abeta oligomers by passive immunization with a conformation selective monoclonal antibody improves learning and memory in APP transgenic mice, J. Biol. Chem, 281, 4292, 10.1074/jbc.m511018200 · DOI
- Gravina S. A., 1995, Amyloid beta protein (A beta) in Alzheimer's disease brain, Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem, 270, 7013
Cited by
Sorted by citations
Items 101–112 of 112
Paganetti, P., Reichwald, J., Bleckmann, D., Abramowski, D., Ammaturo, D., Barske, C., Danner, S., Molinari, M., Müller, M. M., Papin, S., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.013 · Cited by 5
Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
Taylor, R. P., Lindorfer, M. A., & Atkinson, J. P. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12067 · Cited by 5
Conquering the barriers: are antibody therapeutics feasible for CNS indications?
Stanimirovic, D. B., & Kemmerich, K. (2015) · Future Neurology · doi:10.2217/fnl.15.3 · Cited by 5
Challenges in Passive Immunization Strategies to Treat Parkinson Disease
Manfredsson, F. P., Tansey, M. G., & Golde, T. E. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0346 · Cited by 5
Self-citationPassive Immunotherapy in Alzheimer’s Disease
Dolan, P. J., & Zago, W. M. (2018) · InTech eBooks · doi:10.5772/intechopen.76299 · Cited by 4
Wasielewska, J. M., Bajracharya, R., Johnston, R. L., Chaves, J. C. S., Pébay, A., Oikari, L. E., Götz, J., Nisbet, R. M., & White, A. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.24.563706 · Cited by 2
Molecular Mechanism Underlying Aβ Immunotherapy: Implications for the Toxic Action of Aβ Oligomers
Matsubara, E. (2013) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.s2-001 · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Self-citationThe older brain, inflammation, vaccination and the prevention of dementia
Neal, J. (2010) · Reviews in Clinical Gerontology · doi:10.1017/s0959259810000183
Open questions for Alzheimer's disease
Golde, T. E. (2014)
Self-citationTau-Directed Immunotherapy for Alzheimer's Disease
Schroeder, S. K. (2017) · Digital Commons - University of South Florida (University of South Florida)
Therapeutic antibodies as a Wright Brothers' airplane: Clinical proof-of-concept
Saido, T. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28979-8.00015-2
Metadata
- Authors
- Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., Das, P., Golde, T. E., Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., Das, P., & Golde, T. E.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-10-26
- Volume
- 20
- Issue
- 14
- Pages
- 2576-2578
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2091723502
- Semantic Scholar
- 97676444e5cdee032b67a599961944ce98e967f9
- Cited by
- 113
- References
- 60
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 3 · 2018: 8 · 2017: 8 · 2016: 4 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 7
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- anti-amyloid beta antibodies, Alzheimer's disease, amyloid-beta immunotherapy, passive immunization, amyloid-beta clearance, pharmacokinetics, brain penetration, APP transgenic mice
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Monoclonal, Brain, Disease Models, Animal, Female, Immunization, Passive, Mice, Transgenic, Amyloid beta-Peptides, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
